These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 23891508)
1. Clinical significance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non-small-cell lung cancer. Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Iwata T; Uramoto H; So T; Tanaka F Lung Cancer; 2013 Sep; 81(3):475-479. PubMed ID: 23891508 [TBL] [Abstract][Full Text] [Related]
2. Regulatory T-cells and micrometastasis in lymph nodes of stage I NSCLC. Hanagiri T; Fukumoto M; Koyanagi Y; Furutani Y; Tanaka F Anticancer Res; 2014 Dec; 34(12):7185-90. PubMed ID: 25503147 [TBL] [Abstract][Full Text] [Related]
3. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer. Takenoyama M; Yasumoto K; Harada M; Matsuzaki G; Ishida T; Sugimachi K; Nomoto K Immunobiology; 1996 Jul; 195(2):140-51. PubMed ID: 8877391 [TBL] [Abstract][Full Text] [Related]
4. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery. Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703 [TBL] [Abstract][Full Text] [Related]
5. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer. Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581 [TBL] [Abstract][Full Text] [Related]
6. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710 [TBL] [Abstract][Full Text] [Related]
7. Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation. Ke X; Zhang S; Xu J; Liu G; Zhang L; Xie E; Gao L; Li D; Sun R; Wang F; Pan S Cancer Immunol Immunother; 2016 May; 65(5):587-99. PubMed ID: 27000869 [TBL] [Abstract][Full Text] [Related]
8. Clinical significance of expanded Foxp3⁺ Helios⁻ regulatory T cells in patients with non-small cell lung cancer. Muto S; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Suzuki H; Gotoh M Int J Oncol; 2015 Dec; 47(6):2082-90. PubMed ID: 26460798 [TBL] [Abstract][Full Text] [Related]
9. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. Schneider T; Kimpfler S; Warth A; Schnabel PA; Dienemann H; Schadendorf D; Hoffmann H; Umansky V J Thorac Oncol; 2011 Mar; 6(3):432-8. PubMed ID: 21258248 [TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of CD4+ CD25+ regulatory T-cells detection in tumor-draining lymph nodes of nonsmall cell lung cancer patients]. Su YJ; Ren K; Li H; Ren XB; Wang CL Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):922-6. PubMed ID: 18478932 [TBL] [Abstract][Full Text] [Related]
11. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice. Pan XD; Mao YQ; Zhu LJ; Li J; Xie Y; Wang L; Zhang GB Chin Med J (Engl); 2012 Jun; 125(11):2004-11. PubMed ID: 22884069 [TBL] [Abstract][Full Text] [Related]
12. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of regional lymph node lymphocytes in patients with lung cancer. Yaita H; Yasumoto K; Nagashima A; Sugimachi K; Nomoto K J Surg Oncol; 1988 Jul; 38(3):165-72. PubMed ID: 3260643 [TBL] [Abstract][Full Text] [Related]
14. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Nakamura H; Ishiguro K; Mori T Cancer; 1988 Dec; 62(12):2489-97. PubMed ID: 3142676 [TBL] [Abstract][Full Text] [Related]
15. Antitumor response of regional lymph node lymphocytes in human lung cancer. Takenoyama M; Yasumoto K; Harada M; Sugimachi K; Nomoto K Cancer Immunol Immunother; 1998 Dec; 47(4):213-20. PubMed ID: 9875674 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis. Zhao S; Jiang T; Zhang L; Yang H; Liu X; Jia Y; Zhou C Oncotarget; 2016 Jun; 7(24):36065-36073. PubMed ID: 27153545 [TBL] [Abstract][Full Text] [Related]
17. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas. Kayser G; Schulte-Uentrop L; Sienel W; Werner M; Fisch P; Passlick B; Zur Hausen A; Stremmel C Lung Cancer; 2012 Jun; 76(3):445-51. PubMed ID: 22300751 [TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320 [TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453 [TBL] [Abstract][Full Text] [Related]
20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]